Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews...
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • Allergy (Apr 2019)
    • Biology of familial cancer predisposition syndromes (Feb 2019)
    • Mitochondrial dysfunction in disease (Aug 2018)
    • Lipid mediators of disease (Jul 2018)
    • Cellular senescence in human disease (Apr 2018)
    • View all review series...
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Scientific Show Stoppers
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • About
  • Editors
  • Consulting Editors
  • For authors
  • Current issue
  • Past issues
  • By specialty
  • Subscribe
  • Alerts
  • Advertise
  • Contact
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • Brief Reports
  • Technical Advances
  • Commentaries
  • Editorials
  • Hindsight
  • Review series
  • Reviews
  • The Attending Physician
  • First Author Perspectives
  • Scientific Show Stoppers
  • Top read articles
  • Concise Communication
Top
  • View PDF
  • Download citation information
  • Send a letter
  • Terms of use
  • Standard abbreviations
  • Article usage
  • Citations to this article
  • Share this article
  • Need Help? E-mail the JCI
  • Top
  • Abstract
  • Version history

Advertisement

Research Article Free access | 10.1172/JCI117394

Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis.

A P Cope, M Londei, N R Chu, S B Cohen, M J Elliott, F M Brennan, R N Maini, and M Feldmann

Mathilda and Terence Kennedy Institute of Rheumatology, Sunley Division, Hammersmith, London, United Kingdom.

Find articles by Cope, A. in: JCI | PubMed | Google Scholar

Mathilda and Terence Kennedy Institute of Rheumatology, Sunley Division, Hammersmith, London, United Kingdom.

Find articles by Londei, M. in: JCI | PubMed | Google Scholar

Mathilda and Terence Kennedy Institute of Rheumatology, Sunley Division, Hammersmith, London, United Kingdom.

Find articles by Chu, N. in: JCI | PubMed | Google Scholar

Mathilda and Terence Kennedy Institute of Rheumatology, Sunley Division, Hammersmith, London, United Kingdom.

Find articles by Cohen, S. in: JCI | PubMed | Google Scholar

Mathilda and Terence Kennedy Institute of Rheumatology, Sunley Division, Hammersmith, London, United Kingdom.

Find articles by Elliott, M. in: JCI | PubMed | Google Scholar

Mathilda and Terence Kennedy Institute of Rheumatology, Sunley Division, Hammersmith, London, United Kingdom.

Find articles by Brennan, F. in: JCI | PubMed | Google Scholar

Mathilda and Terence Kennedy Institute of Rheumatology, Sunley Division, Hammersmith, London, United Kingdom.

Find articles by Maini, R. in: JCI | PubMed | Google Scholar

Mathilda and Terence Kennedy Institute of Rheumatology, Sunley Division, Hammersmith, London, United Kingdom.

Find articles by Feldmann, M. in: JCI | PubMed | Google Scholar

First published August 1, 1994 - More info

Published in Volume 94, Issue 2 on August 1, 1994
J Clin Invest. 1994;94(2):749–760. https://doi.org/10.1172/JCI117394.
© 1994 The American Society for Clinical Investigation
First published August 1, 1994 - Version history
Abstract

Experiments were designed to test the hypothesis that chronic exposure to tumor necrosis factor alpha (TNF) alters the function of activated T lymphocytes. Pretreatment of tetanus toxoid-specific T cell clones with TNF for up to 16 d impaired rechallenge proliferative responses to antigen in a dose- and time-dependent fashion. IL-2 and PHA responses were preserved. Prolonged treatment with TNF impaired production of IL-2, IL-10, IFN gamma, TNF, and lymphotoxin (LT) following stimulation with immobilized OKT3, and resulted in suboptimal expression of the IL-2R alpha chain (Tac) but not CD3, CD4, or HLA-DR antigens, when compared to untreated control cells. By contrast, pretreatment of T cells for prolonged periods in vitro with neutralizing anti-TNF monoclonal antibodies (mAb) enhanced proliferative responses, increased lymphokine production, and upregulated Tac expression following stimulation with OKT3. To determine whether TNF exerts immunosuppressive effects on T cells in vivo, we studied cell-mediated immunity in patients with active rheumatoid arthritis (RA), before and after treatment with a chimeric anti-TNF mAb. Treatment with anti-TNF restored the diminished proliferative responses of PBMC to mitogens and recall antigens towards normal in all patients tested. These data demonstrate that persistent expression of TNF in vitro and in vivo impairs cell-mediated immune responses.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 749
page 749
icon of scanned page 750
page 750
icon of scanned page 751
page 751
icon of scanned page 752
page 752
icon of scanned page 753
page 753
icon of scanned page 754
page 754
icon of scanned page 755
page 755
icon of scanned page 756
page 756
icon of scanned page 757
page 757
icon of scanned page 758
page 758
icon of scanned page 759
page 759
icon of scanned page 760
page 760
Version history
  • Version 1 (August 1, 1994): No description

Article tools

  • View PDF
  • Download citation information
  • Send a letter
  • Terms of use
  • Standard abbreviations
  • Article usage
  • Citations to this article
  • Share this article
  • Need Help? E-mail the JCI

Go to:

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement
Follow JCI:
Copyright © 2019 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts